StockMacro
Menu

Eli Lilly

$1,347.11 +27% in 6 monthsMarket cap $1.2T

LLY on XNYS, Health Care, Eli Lilly & Co., job postings

Measures activity, not value. Not investment advice.

Quarterly revenue rose 39% to $24.4B and 12-month profit rose 50% to $27.6B.

  • WatchVisa applications for foreign specialists fell 32%, to 350 from 517

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Industry
Pharmaceutical preparations (Health Care)
Employees
50,000
Website
lilly.com
Listed
NYSE, US
Last results
29 Oct 2026
Next results
expected around 3 Feb 2027 (an estimate: a year ago it reported on 4 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $24.4B, net income $6.5B.
Quarter to 31 Dec 2021: revenue $8.0B, net income $1.7BQuarter to 31 Dec 2021: revenue $8.0B, net income $1.7BQuarter to 31 Mar 2022: revenue $7.8B, net income $1.9BQuarter to 31 Mar 2022: revenue $7.8B, net income $1.9BQuarter to 30 Jun 2022: revenue $6.5B, net income $952.5MQuarter to 30 Jun 2022: revenue $6.5B, net income $952.5MQuarter to 30 Sep 2022: revenue $6.9B, net income $1.5BQuarter to 30 Sep 2022: revenue $6.9B, net income $1.5BQuarter to 31 Dec 2022: revenue $7.3B, net income $1.9BQuarter to 31 Dec 2022: revenue $7.3B, net income $1.9BQuarter to 31 Mar 2023: revenue $7.0B, net income $1.3BQuarter to 31 Mar 2023: revenue $7.0B, net income $1.3BQuarter to 30 Jun 2023: revenue $8.3B, net income $1.8BQuarter to 30 Jun 2023: revenue $8.3B, net income $1.8BQuarter to 30 Sep 2023: revenue $9.5B, net income -$57.4MQuarter to 30 Sep 2023: revenue $9.5B, net income -$57.4MQuarter to 31 Dec 2023: revenue $9.4B, net income $2.2BQuarter to 31 Dec 2023: revenue $9.4B, net income $2.2BQuarter to 31 Mar 2024: revenue $8.8B, net income $2.2BQuarter to 31 Mar 2024: revenue $8.8B, net income $2.2BQuarter to 30 Jun 2024: revenue $11.3B, net income $3.0BQuarter to 30 Jun 2024: revenue $11.3B, net income $3.0BQuarter to 30 Sep 2024: revenue $11.4B, net income $970.3MQuarter to 30 Sep 2024: revenue $11.4B, net income $970.3MQuarter to 31 Dec 2024: revenue $13.5B, net income $4.4BQuarter to 31 Dec 2024: revenue $13.5B, net income $4.4BQuarter to 31 Mar 2025: revenue $12.7B, net income $2.8BQuarter to 31 Mar 2025: revenue $12.7B, net income $2.8BQuarter to 30 Jun 2025: revenue $15.6B, net income $5.7BQuarter to 30 Jun 2025: revenue $15.6B, net income $5.7BQuarter to 30 Sep 2025: revenue $17.6B, net income $5.6BQuarter to 30 Sep 2025: revenue $17.6B, net income $5.6BQuarter to 31 Dec 2025: revenue $19.3B, net income $6.6BQuarter to 31 Dec 2025: revenue $19.3B, net income $6.6BQuarter to 31 Mar 2026: revenue $19.8B, net income $7.4BQuarter to 31 Mar 2026: revenue $19.8B, net income $7.4BQuarter to 30 Jun 2026: revenue $23.0B, net income $7.1BQuarter to 30 Jun 2026: revenue $23.0B, net income $7.1BQuarter to 30 Sep 2026: revenue $24.4B, net income $6.5BQuarter to 30 Sep 2026: revenue $24.4B, net income $6.5B
31 Dec 2021RevenueNet incomeNet losstallest bar $24.4B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$24.4B$6.5B
30 Jun 2026$23.0B$7.1B
31 Mar 2026$19.8B$7.4B
31 Dec 2025$19.3B$6.6B
30 Sep 2025$17.6B$5.6B
30 Jun 2025$15.6B$5.7B
31 Mar 2025$12.7B$2.8B
31 Dec 2024$13.5B$4.4B
30 Sep 2024$11.4B$970.3M
30 Jun 2024$11.3B$3.0B
31 Mar 2024$8.8B$2.2B
31 Dec 2023$9.4B$2.2B
30 Sep 2023$9.5B-$57.4M
30 Jun 2023$8.3B$1.8B
31 Mar 2023$7.0B$1.3B
31 Dec 2022$7.3B$1.9B
30 Sep 2022$6.9B$1.5B
30 Jun 2022$6.5B$952.5M
31 Mar 2022$7.8B$1.9B
31 Dec 2021$8.0B$1.7B
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $86.5B $59.4B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +46% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $27.6B $18.4B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $30.81 $20.44
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 83.6% 83.0% 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 31.9% 31.0% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 86.1% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $4.9B $9.9B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $49.5B $42.5B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $44.6B $32.6B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 1.2 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $42.81
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 45.9 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 14.7 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 15.2 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 31.5 2.0
Dividend yieldDividends per share declared in the latest fiscal year divided by the share price. 0.46% 2.5%

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Eli LillyLLY (this company) $1.2T45.914.7+46%31.9%
Johnson & JohnsonJNJ $651.1B40.56.6+7.8%16.2%
AbbvieABBV $505.9B48.97.7+11%15.7%
MerckMRK $329.7B1344.9+4.9%3.6%
Abbott LaboratoriesABT $178.4B37.93.7+10%9.7%
PfizerPFE $156.2B38.72.5+1.3%6.3%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$7.0M

bought $0, sold $7.0M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+1.0%

4,570 13F filers vs 4,526

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

82%

775.6M shares held by 13F filers (30 Sep 2026) of 940.7M outstanding (26 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

0.8%

7.2M shares sold short (30 Oct 2026) of 940.7M outstanding (26 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

2.7

7.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+3.6%

7.0M shares sold short in the report before, 7.2M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

36%

36% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 40%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

-32%

350 vs 517 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+39%

$24.4B vs $17.6B (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$282K

the 12 months before: $0

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$12.5M

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

147

147 articles in the last 7 days; its usual week has 21 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

7.0×

147 articles in the last 7 days; its usual week has 21.

Price $1,347.11 on 20 Nov 2026, +29% over 12 months (12-month range $851.21 to $1,443.50)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $372.5M in the last 12 months (the 12 months before: -$4.2B).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 350 published in the last 12 months, -32% on the 12 months before.
Revenue per quarter. Revenue $24.4B in the latest quarter, +39% on a year earlier.
Capital spending per quarter. Capital spending $617.2M in the latest quarter, +83% on a year earlier.
Institutional holders (13F filers). 4,570 13F filers reported holding it in the latest 13F quarter, +23% on a year earlier.
Federal obligations. Federal obligations: $57K published in the last 12 months, -75% on the 12 months before.
Lobbying spend. Lobbying spend: $12.5M published in the last 12 months, +15% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
30 Jun 2026Sharp changeH-1B/E-3 applications change: h-1B/E-3 applications change, 24 vs usual 7 in the same month of earlier years (2026-02-01..2026-02-28); 2.2x the same month a year earlier
16 Apr 2026Lobbying filinglobbying engagement terminated (DLA PIPER LLP (US))
31 Mar 2026Sharp changeH-1B/E-3 applications change: h-1B/E-3 applications change, 48 vs usual 8 in the same month of earlier years (2025-11-01..2025-11-30); 3.0x the same month a year earlier
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 319 vs usual 170 (2025-12-31); 2.2x the same period a year earlier
18 Dec 2025Sharp changeH-1B/E-3 applications change: h-1B/E-3 applications change, 26 vs usual 10 in the same month of earlier years (2025-08-01..2025-08-31); 2.0x the same month a year earlier
21 Nov 20258-K and other filingsDirector or officer change
21 Nov 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Sep 2025Sharp changeH-1B/E-3 applications change: h-1B/E-3 applications change, 142 vs usual 6 in the same month of earlier years (2025-06-01..2025-06-30); 2.1x the same month a year earlier
13 Aug 2025Sharp changeClustered insider buying: clustered insider buying (5 independent filers, 5 filing(s) in 30 days, value_usd total 2.9M)
15 Jul 2025Lobbying filingnew lobbying registration (B HALL STRATEGIES, LLC)
27 Mar 2025Lobbying filingnew lobbying registration (CHECKMATE GOVERNMENT RELATIONS)
24 Mar 2025Lobbying filingnew lobbying registration (MARSHALL & POPP, LLC)
21 Jan 2025Lobbying filinglobbying engagement terminated (THE SIMMONS & RUSSELL GROUP, LLC)
10 Jan 2025Lobbying filingnew lobbying registration (GRV STRATEGIES LLC)
19 Nov 20248-K and other filingsDirector or officer change
3 Oct 2024Lobbying filingnew lobbying registration (THE HARPLE GROUP, LLC)
17 Sep 2024Sharp changeH-1B/E-3 applications change: h-1B/E-3 applications change, 57 vs usual 10.50 in the same month of earlier years (2024-05-01..2024-05-31); 3.8x the same month a year earlier
9 Sep 20248-K and other filingsDirector or officer change
16 Aug 20248-K and other filingsDirector or officer change
10 Jul 20248-K and other filingsDirector or officer change
2 Jul 2024Lobbying filingnew lobbying registration (DLA PIPER LLP (US))
5 Jun 20248-K and other filingsDirector or officer change
5 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
22 Jan 2024Lobbying filinglobbying engagement terminated (THORN RUN PARTNERS)
16 Jan 2024Sharp changeWikipedia attention spike: wikipedia attention spike, 13K vs usual 7,180.50 (2024-01-08..2024-01-14); 2.2x the same week a year earlier
7 Nov 2023Sharp changeQuarterly revenue change: quarterly revenue change, 9.5B vs usual 7.1B (2023-09-30); 1.4x the same period a year earlier
25 Jul 2023Sharp changeWikipedia attention spike: wikipedia attention spike, 8,676 vs usual 5,406 (2023-07-17..2023-07-23); 2.0x the same week a year earlier
20 Jul 2023Lobbying filinglobbying engagement terminated (CROSSROADS STRATEGIES, LLC)
2 May 2023Sharp changeShort interest spike: short interest spike, 7.6M vs usual 5.4M (2023-04-14); 1.2x the same period a year earlier
20 Apr 2023Lobbying filingnew lobbying registration (TODD STRATEGY GROUP)
28 Mar 2023Sharp changeShort interest spike: short interest spike, 8.1M vs usual 5.4M (2023-03-15); 1.2x the same period a year earlier
17 Mar 20238-K and other filingsDirector or officer change
17 Mar 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Mar 2023Sharp changeWikipedia attention spike: wikipedia attention spike, 13K vs usual 5,175 (2023-02-27..2023-03-05); 3.2x the same week a year earlier
15 Nov 2022Sharp changeWikipedia attention spike: wikipedia attention spike, 49K vs usual 4,542 (2022-11-07..2022-11-13); 11.9x the same week a year earlier
8 Nov 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 617.2M vs usual 351.1M (2022-09-30); 1.8x the same period a year earlier
4 Oct 2022Sharp changeH-1B/E-3 applications change: h-1B/E-3 applications change, 50 vs usual 3 in the same month of earlier years (2022-05-01..2022-05-31); 8.3x the same month a year earlier
9 Aug 2022Sharp changeWikipedia attention spike: wikipedia attention spike, 8,353 vs usual 4,379.50 (2022-08-01..2022-08-07); 1.5x the same week a year earlier
6 May 20228-K and other filingsDirector or officer change
6 May 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: -$106.5M published
Month from 1 Jan 2022: -$1.0M published
Month from 1 Feb 2022: -$480K published
Month from 1 Mar 2022: -$360.1M published
Month from 1 Apr 2022: -$174.9M published
Month from 1 May 2022: -$165.6M published
Month from 1 Jun 2022: -$276.1M published
Month from 1 Jul 2022: -$94.6M published
Month from 1 Aug 2022: -$203 published
Month from 1 Sep 2022: -$34.4M published
Month from 1 Oct 2022: -$138.1M published
Month from 1 Nov 2022: -$74.3M published
Month from 1 Dec 2022: -$78.1M published
Month from 1 Feb 2023: -$1.7M published
Month from 1 Mar 2023: -$67.7M published
Month from 1 Apr 2023: -$216.9M published
Month from 1 May 2023: -$278.2M published
Month from 1 Jun 2023: -$106.8M published
Month from 1 Jul 2023: -$103.0M published
Month from 1 Aug 2023: -$398.4M published
Month from 1 Sep 2023: -$149.9M published
Month from 1 Oct 2023: -$130.2M published
Month from 1 Nov 2023: -$383K published
Month from 1 Jan 2024: -$177.6M published
Month from 1 Feb 2024: -$430.1M published
Month from 1 Mar 2024: -$565K published
Month from 1 May 2024: -$383.9M published
Month from 1 Jun 2024: -$916.3M published
Month from 1 Jul 2024: -$394.5M published
Month from 1 Aug 2024: -$27.6M published
Month from 1 Sep 2024: -$23.3M published
Month from 1 Nov 2024: -$723K published
Month from 1 Feb 2025: -$583.5M published
Month from 1 Mar 2025: -$205.1M published
Month from 1 May 2025: -$1.7M published
Month from 1 Jul 2025: -$225.4M published
Month from 1 Aug 2025: $3.0M published
Month from 1 Sep 2025: -$99.6M published
Month from 1 Oct 2025: -$883.4M published
Month from 1 Nov 2025: -$2.2B published
Month from 1 Dec 2025: -$7.0M published
Month from 1 Jan 2026: -$323.9M published
Month from 1 May 2026: -$15.8M published
Month from 1 Jun 2026: -$2.9M published
Month from 1 Aug 2026: -$16.0M published
Month from 1 Nov 2026: -$7.0M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 17 published
Quarter from 1 Apr 2022: 27 published
Quarter from 1 Jul 2022: 67 published
Quarter from 1 Oct 2022: 19 published
Quarter from 1 Jan 2023: 23 published
Quarter from 1 Apr 2023: 24 published
Quarter from 1 Jul 2023: 74 published
Quarter from 1 Oct 2023: 43 published
Quarter from 1 Jan 2024: 28 published
Quarter from 1 Apr 2024: 23 published
Quarter from 1 Jul 2024: 137 published
Quarter from 1 Oct 2024: 48 published
Quarter from 1 Jan 2025: 59 published
Quarter from 1 Apr 2025: 35 published
Quarter from 1 Jul 2025: 310 published
Quarter from 1 Oct 2025: 113 published
Quarter from 1 Jan 2026: 76 published
Quarter from 1 Apr 2026: 98 published
Quarter from 1 Jul 2026: 133 published
Quarter from 1 Oct 2026: 43 published
Revenue per quarter
Quarter ended 31 Dec 2021: $8.0B; public on 24 Feb 2022
Quarter ended 31 Mar 2022: $7.8B, +15% on a year earlier; public on 30 Apr 2022
Quarter ended 30 Jun 2022: $6.5B, -3.7% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $6.9B, +2.5% on a year earlier; public on 2 Nov 2022
Quarter ended 31 Dec 2022: $7.3B, -8.7% on a year earlier; public on 23 Feb 2023
Quarter ended 31 Mar 2023: $7.0B, -11% on a year earlier; public on 28 Apr 2023
Quarter ended 30 Jun 2023: $8.3B, +28% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $9.5B, +37% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $9.4B, +28% on a year earlier; public on 22 Feb 2024
Quarter ended 31 Mar 2024: $8.8B, +26% on a year earlier; public on 1 May 2024
Quarter ended 30 Jun 2024: $11.3B, +36% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $11.4B, +20% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $13.5B, +45% on a year earlier; public on 20 Feb 2025
Quarter ended 31 Mar 2025: $12.7B, +45% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $15.6B, +38% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $17.6B, +54% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $19.3B, +43% on a year earlier; public on 13 Feb 2026
Quarter ended 31 Mar 2026: $19.8B, +56% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $23.0B, +48% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $24.4B, +39% on a year earlier; public on 30 Oct 2026
Capital spending per quarter
Quarter ended 31 Mar 2022: $365.4M, +22% on a year earlier; public on 30 Apr 2022
Quarter ended 30 Jun 2022: $371.0M, -2.7% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $617.2M, +83% on a year earlier; public on 2 Nov 2022
Institutional holders (13F filers)
31 Dec 2021 report: 2,034; public on 14 Feb 2022
31 Mar 2022 report: 2,187; public on 16 May 2022
30 Jun 2022 report: 2,281; public on 15 Aug 2022
30 Sep 2022 report: 2,267; public on 14 Nov 2022
31 Dec 2022 report: 2,430; public on 14 Feb 2023
31 Mar 2023 report: 2,430; public on 15 May 2023
30 Jun 2023 report: 2,577; public on 14 Aug 2023
30 Sep 2023 report: 2,727; public on 14 Nov 2023
31 Dec 2023 report: 2,999; public on 14 Feb 2024
31 Mar 2024 report: 3,245; public on 15 May 2024
30 Jun 2024 report: 3,347; public on 14 Aug 2024
30 Sep 2024 report: 3,435; public on 14 Nov 2024
31 Dec 2024 report: 3,646; public on 14 Feb 2025
31 Mar 2025 report: 3,737; public on 15 May 2025
30 Jun 2025 report: 3,730; public on 14 Aug 2025
30 Sep 2025 report: 3,712; public on 14 Nov 2025
31 Dec 2025 report: 4,204; public on 17 Feb 2026
31 Mar 2026 report: 4,240; public on 15 May 2026
30 Jun 2026 report: 4,526; public on 14 Aug 2026
30 Sep 2026 report: 4,570; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: $329.8M published
Month from 1 Feb 2022: $1.3B published
Month from 1 Apr 2022: $0 published
Month from 1 May 2022: $1.1B published
Month from 1 Sep 2022: $273.8M published
Month from 1 Nov 2022: $0 published
Month from 1 Dec 2022: $109.5M published
Month from 1 May 2023: $0 published
Month from 1 Oct 2025: $230K published
Month from 1 May 2026: $52K published
Month from 1 Aug 2026: $2K published
Month from 1 Sep 2026: $2K published
Lobbying spend
Quarter from 1 Jan 2022: $2.4M published
Quarter from 1 Apr 2022: $1.7M published
Quarter from 1 Jul 2022: $2.2M published
Quarter from 1 Oct 2022: $1.4M published
Quarter from 1 Jan 2023: $2.2M published
Quarter from 1 Apr 2023: $1.7M published
Quarter from 1 Jul 2023: $1.8M published
Quarter from 1 Oct 2023: $2.4M published
Quarter from 1 Jan 2024: $2.7M published
Quarter from 1 Apr 2024: $1.9M published
Quarter from 1 Jul 2024: $2.6M published
Quarter from 1 Oct 2024: $1.9M published
Quarter from 1 Jan 2025: $2.0M published
Quarter from 1 Apr 2025: $3.5M published
Quarter from 1 Jul 2025: $2.9M published
Quarter from 1 Oct 2025: $2.5M published
Quarter from 1 Jan 2026: $2.4M published
Quarter from 1 Apr 2026: $3.9M published
Quarter from 1 Jul 2026: $3.4M published
Quarter from 1 Oct 2026: $2.8M published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is wikipedia page views (human, all devices) at 11K (week of 9 Nov 2026), 1.3× its normal week; higher than 84% of its own history.
  • H-1B/E-3 applications change: had 24 H-1B/E-3 visa applications certified in February 2026, 2.2× the same month last year Public on 29 Jun 2026.
  • Insider net buying (open market): Insiders sold a net $372.5M in the last 12 months (the 12 months before: -$4.2B).
  • Revenue per quarter: Revenue $24.4B in the latest quarter, +39% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 1 sale, $7.0M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
3 Nov 2026Anat HakimEVP, GC & SecretarySellplanned in advance (10b5-1)5,000$1,402.52$7.0MForm 4
18 Aug 2026Patrik JonssonEVP & President, LLY Int'lSellplanned in advance (10b5-1)6,500$1,175.10$7.6MForm 4
11 Aug 2026Donald A ZakrowskiSVP, Finance, & CAOSellplanned in advance (10b5-1)2,000$1,185.01$2.4MForm 4
10 Aug 2026Anat HakimEVP, GC & SecretarySellplanned in advance (10b5-1)5,000$1,190.00$6.0MForm 4
11 Jun 2026Ilya YuffaEVP&Pres, LLY USA&Global CapabSellplanned in advance (10b5-1)2,500$1,150.77$2.9MForm 4
7 May 2026Lilly Endowment IncFormer 10% ShareholderSell15,828$995.36$15.8MForm 4
8 Jan 2026Lilly Endowment Inc10% ownerSell292,148$1,103.48$322.4MForm 4
6 Jan 2026Lilly Endowment Inc10% ownerSell1,390$1,085.01$1.5MForm 4

4,570 institutions reported shares at the end of Q3 2026, 82% of the shares outstanding; 157 opened a position, 137 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Lilly Endowment Inc90.1M9.57%$104.2B-310K-0.3%
BlackRock, Inc.67.9M7.22%$78.6B+396K+0.6%
Vanguard Capital Management LLC53.9M5.73%$62.4B+392K+0.7%
PNC Financial Services Group, Inc.51.3M5.45%$59.4B-28K-0.1%
State Street Corp36.8M3.92%$42.6B+633K+1.7%
FMR LLC (Fidelity)30.0M3.18%$34.7B+1.5M+5.3%
Vanguard Portfolio Management LLC21.0M2.23%$24.3B+141K+0.7%
Geode Capital Management, LLC20.6M2.19%$23.7B+246K+1.2%
Capital Research Global Investors17.0M1.81%$19.7B-3.9M-19%
Morgan Stanley16.4M1.74%$19.0B+151K+0.9%

Federal contracts

All 5 federal contracts

No new award in 12 months; the latest was signed 10 Feb 2022. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
10 Feb 2022Department of DefenseDepartment of the Army$1.5Bup to $2.1BLYCOV1404 BEBTELOVIMABUSAspending
1 Nov 2021Department of DefenseDepartment of the Army$1.3BPURCHASE OF A TOTAL OF 614,000 DOSES OF COMBINATION MONOCLONAL ANTIBODY.USAspending
14 Sep 2021Department of DefenseDepartment of the Army$329.8MPURCHASE OF 388,000 DOSES OF MONOCLONAL ANTIBODY LY-COV016.USAspending
25 Feb 2021Department of DefenseDepartment of the Army$210.0MCOMBINATION MONOCLONAL ANTIBODY - DELIVERY ORDER FOR 100,000 DOSES.USAspending
27 Oct 2020Department of DefenseDepartment of the Army$1.4BMONOCLONAL ANTIBODY LY-COV555USAspending

Company events

All 23 company events

Nothing in 12 months; the latest was filed 21 Nov 2025. Results releases and routine reports are left out.

FiledWhat happenedSource
21 Nov 2025Director or officer change8-K
19 Nov 2024Director or officer change8-K
9 Sep 2024Director or officer change8-K
16 Aug 2024Director or officer change8-K
10 Jul 2024Director or officer change8-K
5 Jun 2024Director or officer change8-K
17 Mar 2023Director or officer change8-K
6 May 2022Director or officer change8-K

Reported lobbying spend: $2.8M in Q3 2026, $3.4M in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Jan 2026EndedDla Piper LLP (US)for Eli Lilly & CompanyNot statedFiling
1 Apr 2025NewB Hall Strategies, LLCfor Tiber Creek Health Strategies, Inc. On Behalf Of Eli Lilly And CompanyIssues related to drug pricing and reimbursement for prescription drugs.Medicare/MedicaidFiling
14 Mar 2025NewMarshall & Popp, LLCfor Eli Lilly And CompanyIssues related to treatments for Alzheimers therapeutics.Health issues, Medicare/Medicaid, Taxation, BudgetFiling
1 Mar 2025NewCheckmate Government Relationsfor Eli Lilly And CompanyIssues related to healthcare and trade.Health issues, TradeFiling
1 Jan 2025NewGRV Strategies LLCfor Eli Lilly And CompanyIssues related to healthcare and trade.Health issues, Medicare/Medicaid, TradeFiling
31 Dec 2024EndedThe Simmons & Russell Group, LLCfor Eli Lilly And CompanyIssues related to the pharmaceutical industry including healthcare policy, drug pricing, drug value, insulin, and the 340B Program. Monitoring implementation of the Inflation Reduction Act of 2022, H.R.5376, P.L.117-169. Monitoring implementation of the Infrastructure Investment and Jobs Act, H.R.36; Issues related to tax legislation; Tax Relief for American Families and Workers Act of 2024, H.R.7024.Pharmacy, TaxationFiling
18 Jul 2024NewThe Harple Group, LLCfor Eli Lilly & CompanyPharmaceutical supply chain security and resiliency.Health issuesFiling
21 Jun 2024NewDla Piper LLP (US)for Eli Lilly & CompanyPharmaceutical supply chain security and resiliency.Health issuesFiling

Layoff notices

All 1 layoff notices

No notice in 12 months; the latest is dated 1 Oct 2017. State WARN notices.

NoticeSiteWorkersJobs endSource
1 Oct 2017Eli LillyBridgewater, NJ7831 Jan 2018Notice

The 5 newest of 1,406 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

2 Sep 2025confirmed

Confirmed across sources Hiring and Insiders

Eli Lilly (LLY): had 5 insiders buy $2.9M of its shares on the open market within 30 days (5 filings), while it had 142 H-1B/E-3 visa applications certified in June 2025, 2.1× the same month last year. Two unrelated kinds of activity within 20 days.

  • Insiders: Clustered insider buying, became public on 13 Aug 2025
  • Hiring: H-1B/E-3 applications change, became public on 31 Aug 2025
2020-06-01: 02021-06-01: 32022-06-01: 62023-06-01: 532024-06-01: 692025-06-01: 142
June 2025 against the 5 months before it. this monthearliernormal: 6
See the evidence (2 changes)

Insiders: Clustered insider buying became public on 13 Aug 2025

Eli Lilly had 5 insiders buy $2.9M of its shares on the open market within 30 days (5 filings).

Independent buyers
5
Purchase filings (Form 4, code P)
5
Total bought
$2.9M
Window
14 Jul 2025 to 13 Aug 2025

Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

Hiring: H-1B/E-3 applications change became public on 31 Aug 2025

Eli Lilly had 142 H-1B/E-3 visa applications certified in June 2025, 2.1× the same month last year.

This period
142 (June 2025)
Normal month (median of 5 earlier)
6
Typical spread (median absolute deviation)
6
How far from its usual level
+15.3
Same month last year
69
History used
2,079 days
2020-06-01: 02021-06-01: 32022-06-01: 62023-06-01: 532024-06-01: 692025-06-01: 142
June 20255 earlier monthsnormal: 6

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.

Check it at the source: DOL foreign labor disclosure data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

28 Mar 2023confirmed

Confirmed across sources Attention and Short interest and volume

Eli Lilly (LLY): drew 13K Wikipedia page views in the week of 27 Feb 2023, 3.2× the same week last year, while it had 8.1M shares sold short in the 15 Mar 2023 report, 1.2× the same report last year. Two unrelated kinds of activity within 21 days.

  • Attention: Wikipedia attention spike, became public on 7 Mar 2023
  • Short interest and volume: Short interest spike, became public on 25 Mar 2023
2022-08-29: 4,3932022-09-05: 4,2692022-09-12: 4,8352022-09-19: 5,4232022-09-26: 5,5142022-10-03: 4,8302022-10-10: 5,1832022-10-17: 4,9552022-10-24: 5,1372022-10-31: 5,8672022-11-07: 49K2022-11-14: 21K2022-11-21: 7,3292022-11-28: 6,7752022-12-05: 5,3532022-12-12: 5,0872022-12-19: 4,2672022-12-26: 4,2102023-01-02: 5,6152023-01-09: 5,7692023-01-16: 5,3582023-01-23: 5,0432023-01-30: 5,5602023-02-06: 5,1672023-02-13: 4,8472023-02-20: 5,0002023-02-27: 13K
The week of 27 Feb 2023 against the 26 weeks before it. this weekearliernormal: 5,175
See the evidence (2 changes)

Attention: Wikipedia attention spike became public on 7 Mar 2023

Eli Lilly drew 13K Wikipedia page views in the week of 27 Feb 2023, 3.2× the same week last year.

This period
13K (the week of 27 Feb 2023)
Normal week (median of 26 earlier)
5,175
Typical spread (median absolute deviation)
342
How far from its usual level
+14.7
Same week last year
4,012
History used
1,524 days
2022-08-29: 4,3932022-09-05: 4,2692022-09-12: 4,8352022-09-19: 5,4232022-09-26: 5,5142022-10-03: 4,8302022-10-10: 5,1832022-10-17: 4,9552022-10-24: 5,1372022-10-31: 5,8672022-11-07: 49K2022-11-14: 21K2022-11-21: 7,3292022-11-28: 6,7752022-12-05: 5,3532022-12-12: 5,0872022-12-19: 4,2672022-12-26: 4,2102023-01-02: 5,6152023-01-09: 5,7692023-01-16: 5,3582023-01-23: 5,0432023-01-30: 5,5602023-02-06: 5,1672023-02-13: 4,8472023-02-20: 5,0002023-02-27: 13K
the week of 27 Feb 202326 earlier weeksnormal: 5,175

Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

Check it at the source: Wikimedia page view statistics.

Short interest and volume: Short interest spike became public on 25 Mar 2023

Eli Lilly had 8.1M shares sold short in the 15 Mar 2023 report, 1.2× the same report last year.

This period
8.1M (the 15 Mar 2023 report)
Normal report (median of 24 earlier)
5.4M
Typical spread (median absolute deviation)
394K
How far from its usual level
+4.7
Same report last year
6.6M
History used
1,902 days
2022-03-15: 6.6M2022-03-31: 5.8M2022-04-14: 6.2M2022-04-29: 5.0M2022-05-13: 5.2M2022-05-31: 5.1M2022-06-15: 4.3M2022-06-30: 4.9M2022-07-15: 5.5M2022-07-29: 5.0M2022-08-15: 4.8M2022-08-31: 5.2M2022-09-15: 5.3M2022-09-30: 5.8M2022-10-14: 5.4M2022-10-31: 6.1M2022-11-15: 5.6M2022-11-30: 6.6M2022-12-15: 5.6M2022-12-30: 5.6M2023-01-13: 4.9M2023-01-31: 4.9M2023-02-15: 5.2M2023-02-28: 6.8M2023-03-15: 8.1M
the 15 Mar 2023 report24 earlier reportsnormal: 5.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

15 Nov 2022confirmed

Confirmed across sources Attention and Filings + Financials

Eli Lilly (LLY): spent $617.2M on capital projects in the quarter ended 30 Sep 2022, 1.8× the same quarter last year, while it drew 49K Wikipedia page views in the week of 7 Nov 2022, 12× the same week last year. Two unrelated kinds of activity within 7 days.

  • Financials: Quarterly capital spending jump, became public on 8 Nov 2022
  • Attention: Wikipedia attention spike, became public on 15 Nov 2022
2020-03-31: $258.3M2020-06-30: $281.8M2020-09-30: $393.1M2021-03-31: $300.3M2021-06-30: $381.3M2021-09-30: $336.8M2022-03-31: $365.4M2022-06-30: $371.0M2022-09-30: $617.2M
The quarter ended 30 Sep 2022 against the 8 quarters before it. this quarterearliernormal: $351.1M
See the evidence (2 changes)

Financials: Quarterly capital spending jump became public on 8 Nov 2022

Eli Lilly spent $617.2M on capital projects in the quarter ended 30 Sep 2022, 1.8× the same quarter last year.

This period
$617.2M (the quarter ended 30 Sep 2022)
Normal quarter (median of 8 earlier)
$351.1M
Typical spread (median absolute deviation)
$36.1M
How far from its usual level
+5.0
Same quarter last year
$336.8M
History used
1,279 days
2020-03-31: $258.3M2020-06-30: $281.8M2020-09-30: $393.1M2021-03-31: $300.3M2021-06-30: $381.3M2021-09-30: $336.8M2022-03-31: $365.4M2022-06-30: $371.0M2022-09-30: $617.2M
the quarter ended 30 Sep 20228 earlier quartersnormal: $351.1M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Attention: Wikipedia attention spike became public on 15 Nov 2022

Eli Lilly drew 49K Wikipedia page views in the week of 7 Nov 2022, 12× the same week last year.

This period
49K (the week of 7 Nov 2022)
Normal week (median of 26 earlier)
4,542
Typical spread (median absolute deviation)
285
How far from its usual level
+98.3
Same week last year
4,123
History used
1,412 days
2022-05-09: 4,4692022-05-16: 4,5082022-05-23: 4,1292022-05-30: 4,3712022-06-06: 4,8222022-06-13: 4,5762022-06-20: 4,0912022-06-27: 3,9892022-07-04: 4,2742022-07-11: 4,4402022-07-18: 4,2602022-07-25: 4,3712022-08-01: 8,3532022-08-08: 5,7152022-08-15: 4,8192022-08-22: 4,2982022-08-29: 4,3932022-09-05: 4,2692022-09-12: 4,8352022-09-19: 5,4232022-09-26: 5,5142022-10-03: 4,8302022-10-10: 5,1832022-10-17: 4,9552022-10-24: 5,1372022-10-31: 5,8672022-11-07: 49K
the week of 7 Nov 202226 earlier weeksnormal: 4,542

Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

Check it at the source: Wikimedia page view statistics.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 13 Nov 2026Institutional holdings record

    GQG Partners LLC opened a $878.0M position (2026Q3 13F)

  2. 29 Jun 2026Hiring change

    had 24 H-1B/E-3 visa applications certified in February 2026, 2.2× the same month last year.

    Same month last year: 11; its normal month is 7.

    See the evidence
    This period
    24 (February 2026)
    Normal month (median of 5 earlier)
    7
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +5.7
    Same month last year
    11
    History used
    2,322 days
    2021-02-01: 52022-02-01: 82023-02-01: 72024-02-01: 52025-02-01: 112026-02-01: 24
    February 20265 earlier monthsnormal: 7

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.

    Check it at the source: DOL foreign labor disclosure data.

  3. 16 Apr 2026Lobbying record

    ELI LILLY & COMPANY: lobbying engagement terminated (DLA PIPER LLP (US)) (dated 1 Jan 2026)

  4. 31 Mar 2026Hiring change

    had 48 H-1B/E-3 visa applications certified in November 2025, 3.0× the same month last year.

    Same month last year: 16; its normal month is 8.

    See the evidence
    This period
    48 (November 2025)
    Normal month (median of 5 earlier)
    8
    Typical spread (median absolute deviation)
    6
    How far from its usual level
    +4.5
    Same month last year
    16
    History used
    2,232 days
    2020-11-01: 22021-11-01: 82022-11-01: 82023-11-01: 152024-11-01: 162025-11-01: 48
    November 20255 earlier monthsnormal: 8

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.

    Check it at the source: DOL foreign labor disclosure data.

  5. 17 Feb 2026Institutional holdings change

    saw 319 13F filers open a new position in the quarter ended 31 Dec 2025, 2.2× the same quarter last year.

    Same quarter last year: 146; its normal quarter is 170.

    See the evidence
    This period
    319 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    170
    Typical spread (median absolute deviation)
    14
    How far from its usual level
    +7.2
    Same quarter last year
    146
    History used
    4,475 days
    2023-12-31: 1712024-03-31: 2542024-06-30: 1992024-09-30: 1692024-12-31: 1462025-03-31: 1872025-06-30: 1592025-09-30: 1592025-12-31: 319
    the quarter ended 31 Dec 20258 earlier quartersnormal: 170

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  6. 18 Dec 2025Hiring change

    had 26 H-1B/E-3 visa applications certified in August 2025, 2.0× the same month last year.

    Same month last year: 13; its normal month is 10.

    See the evidence
    This period
    26 (August 2025)
    Normal month (median of 5 earlier)
    10
    Typical spread (median absolute deviation)
    3
    How far from its usual level
    +3.6
    Same month last year
    13
    History used
    2,141 days
    2020-08-01: 62021-08-01: 102022-08-01: 52023-08-01: 102024-08-01: 132025-08-01: 26
    August 20255 earlier monthsnormal: 10

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.

    Check it at the source: DOL foreign labor disclosure data.

  7. 21 Nov 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 21 Nov 2025Filings record

    Director or officer change

  9. 2 Sep 2025several at once

    had 5 insiders buy $2.9M of its shares on the open market within 30 days (5 filings), while it had 142 H-1B/E-3 visa applications certified in June 2025, 2.1× the same month last year. Two unrelated kinds of activity within 20 days.

    See the evidence (2 changes)

    Insiders: Clustered insider buying became public on 13 Aug 2025

    Eli Lilly had 5 insiders buy $2.9M of its shares on the open market within 30 days (5 filings).

    Independent buyers
    5
    Purchase filings (Form 4, code P)
    5
    Total bought
    $2.9M
    Window
    14 Jul 2025 to 13 Aug 2025

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

    Hiring: H-1B/E-3 applications change became public on 31 Aug 2025

    Eli Lilly had 142 H-1B/E-3 visa applications certified in June 2025, 2.1× the same month last year.

    This period
    142 (June 2025)
    Normal month (median of 5 earlier)
    6
    Typical spread (median absolute deviation)
    6
    How far from its usual level
    +15.3
    Same month last year
    69
    History used
    2,079 days
    2020-06-01: 02021-06-01: 32022-06-01: 62023-06-01: 532024-06-01: 692025-06-01: 142
    June 20255 earlier monthsnormal: 6

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.

    Check it at the source: DOL foreign labor disclosure data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  10. 31 Aug 2025Hiring change

    had 142 H-1B/E-3 visa applications certified in June 2025, 2.1× the same month last year.

    Same month last year: 69; its normal month is 6.

    See the evidence
    This period
    142 (June 2025)
    Normal month (median of 5 earlier)
    6
    Typical spread (median absolute deviation)
    6
    How far from its usual level
    +15.3
    Same month last year
    69
    History used
    2,079 days
    2020-06-01: 02021-06-01: 32022-06-01: 62023-06-01: 532024-06-01: 692025-06-01: 142
    June 20255 earlier monthsnormal: 6

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.

    Check it at the source: DOL foreign labor disclosure data.

  11. 16 Aug 2025Insiders record

    Montarce Lucas (EVP & CFO) bought 715 shares of LLY ($494,630) (dated 15 Aug 2025)

  12. 15 Aug 2025Insiders record

    Alvarez Ralph (director) bought 758 shares of LLY ($500,470) (dated 14 Aug 2025)

  13. 14 Aug 2025Institutional holdings record

    VIKING GLOBAL INVESTORS LP opened a $325.0M position (2025Q2 13F)

  14. 14 Aug 2025Insiders record

    Van Naarden Jacob (EVP & Pres., Lilly Oncology) bought 1,000 shares of LLY ($647,360) (dated 13 Aug 2025)

  15. 13 Aug 2025Insiders change

    had 5 insiders buy $2.9M of its shares on the open market within 30 days (5 filings).

    Who bought: Jackson Jamere, Skovronsky Daniel, Fyrwald J Erik, Sulzberger Gabrielle and 1 more.

    See the evidence (5 source records)
    Independent buyers
    5
    Purchase filings (Form 4, code P)
    5
    Total bought
    $2.9M
    Window
    14 Jul 2025 to 13 Aug 2025

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  16. 13 Aug 2025Insiders record

    Ricks David A (President, Chair, and CEO) bought 1,632 shares of LLY ($1.1M) (dated 12 Aug 2025)

  17. 13 Aug 2025Insiders record

    Sulzberger Gabrielle (director) bought 117 shares of LLY ($75,018) (dated 12 Aug 2025)

  18. 13 Aug 2025Insiders record

    Fyrwald J Erik (director) bought 1,565 shares of LLY ($1.0M) (dated 12 Aug 2025)

  19. 13 Aug 2025Insiders record

    Skovronsky Daniel (EVP, CSO & Pres. LRL & LLY Imm) bought 1,000 shares of LLY ($634,410) (dated 12 Aug 2025)

  20. 9 Aug 2025Insiders record

    JACKSON JAMERE (director) bought 200 shares of LLY ($127,912) (dated 8 Aug 2025)

  21. 15 Jul 2025Lobbying record

    TIBER CREEK HEALTH STRATEGIES, INC. ON BEHALF OF ELI LILLY AND COMPANY: new lobbying registration (B HALL STRATEGIES, LLC) (dated 1 Apr 2025)

  22. 27 Mar 2025Lobbying record

    ELI LILLY AND COMPANY: new lobbying registration (CHECKMATE GOVERNMENT RELATIONS) (dated 1 Mar 2025)

  23. 24 Mar 2025Lobbying record

    ELI LILLY AND COMPANY: new lobbying registration (MARSHALL & POPP, LLC) (dated 14 Mar 2025)

  24. 14 Feb 2025Institutional holdings record

    LONE PINE CAPITAL LLC opened a $604.0M position (2024Q4 13F)

  25. 21 Jan 2025Lobbying record

    ELI LILLY AND COMPANY: lobbying engagement terminated (THE SIMMONS & RUSSELL GROUP, LLC) (dated 31 Dec 2024)

  26. 10 Jan 2025Lobbying record

    ELI LILLY AND COMPANY: new lobbying registration (GRV STRATEGIES LLC) (dated 1 Jan 2025)

  27. 19 Nov 2024Filings record

    Director or officer change

  28. 3 Oct 2024Lobbying record

    ELI LILLY & COMPANY: new lobbying registration (THE HARPLE GROUP, LLC) (dated 18 Jul 2024)

  29. 13 Sep 2024Hiring change

    had 57 H-1B/E-3 visa applications certified in May 2024, 3.8× the same month last year.

    Same month last year: 15; its normal month is 10.5.

    See the evidence
    This period
    57 (May 2024)
    Normal month (median of 4 earlier)
    10.5
    Typical spread (median absolute deviation)
    7.5
    How far from its usual level
    +4.2
    Same month last year
    15
    History used
    1,684 days
    2020-05-01: 02021-05-01: 62022-05-01: 502023-05-01: 152024-05-01: 57
    May 20244 earlier monthsnormal: 10.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.

    Check it at the source: DOL foreign labor disclosure data.

  30. 9 Sep 2024Filings record

    Director or officer change

  31. 16 Aug 2024Filings record

    Director or officer change

  32. 14 Aug 2024Institutional holdings record

    Hudson Bay Capital Management LP opened a $353.0M position (2024Q2 13F)

  33. 10 Jul 2024Filings record

    Director or officer change

  34. 2 Jul 2024Lobbying record

    ELI LILLY & COMPANY: new lobbying registration (DLA PIPER LLP (US)) (dated 21 Jun 2024)

  35. 5 Jun 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  36. 5 Jun 2024Filings record

    Director or officer change

  37. 22 Jan 2024Lobbying record

    ELI LILLY AND COMPANY: lobbying engagement terminated (THORN RUN PARTNERS) (dated 31 Dec 2023)

  38. 16 Jan 2024Attention change

    drew 13K Wikipedia page views in the week of 8 Jan 2024, 2.2× the same week last year.

    Same week last year: 5,769; its normal week is 7,180.

    See the evidence
    This period
    13K (the week of 8 Jan 2024)
    Normal week (median of 26 earlier)
    7,180
    Typical spread (median absolute deviation)
    700
    How far from its usual level
    +5.4
    Same week last year
    5,769
    History used
    1,839 days
    2023-07-10: 5,4612023-07-17: 8,6762023-07-24: 5,6152023-07-31: 5,4842023-08-07: 8,5402023-08-14: 6,4052023-08-21: 7,3152023-08-28: 7,0282023-09-04: 7,6172023-09-11: 7,2422023-09-18: 6,5042023-09-25: 6,2022023-10-02: 6,4702023-10-09: 6,7812023-10-16: 6,6722023-10-23: 7,0722023-10-30: 8,0442023-11-06: 10K2023-11-13: 9,2542023-11-20: 6,7712023-11-27: 7,8712023-12-04: 7,7702023-12-11: 8,5932023-12-18: 7,5572023-12-25: 7,1192024-01-01: 10K2024-01-08: 13K
    the week of 8 Jan 202426 earlier weeksnormal: 7,180

    Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

    Check it at the source: Wikimedia page view statistics.

  39. 13 Nov 2023Institutional holdings record

    POLEN CAPITAL MANAGEMENT LLC opened a $335.0M position (2023Q3 13F)

  40. 8 Nov 2023Institutional holdings record

    J.P. Morgan Private Wealth Advisors LLC opened a $436.0M position (2023Q3 13F)

Showing the newest 40 of 159 entries; narrow the window or the kind of data to see older ones.

Not listed: 532 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000059478
Ticker
LLY
Domain
lilly.com
Employer name
Eli Lilly and Company, Lilly USA, LLC (2 unverified)
Fein
26-3011712 (1 unverified)
Hq location
IN|INDIANAPOLIS|46285 (1 unverified)
Lobbying client
eli lillly, eli lilly, eli lilly and company fka lilly usa, tiber creek health strategies inc on behalf of eli lilly
Name
Adverum Biotechnologies, Inc, Adverum NC, LLC, Akouos, Inc, Alnara Pharmaceuticals, Inc and 153 more
Uei
UHHVNTY54K68
Wikidata
Q632240
Wikipedia
Eli Lilly and Company
  • DOL H-1B labor condition applications and PERM certifications1380 data points21 Oct 2019 to 21 Sep 2026
  • Federal lobbying disclosures (LDA)123 records, 279 data points1 Jan 1999 to 30 Sep 2026
  • SEC Form 13F institutional holdings11 records, 481 data points30 Jun 2013 to 13 Nov 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)138 records19 Feb 2016 to 29 Oct 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1039 data points31 Dec 2006 to 26 Oct 2026
  • SEC Form 4 insider transactions444 records, 1576 data points2 Feb 2016 to 3 Nov 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards5 records, 105 data points25 Oct 2007 to 1 Sep 2026
  • WARN layoff notices (state labor agencies)1 record, 3 data points25 Sep 2017 to 1 Oct 2017
  • Wikipedia pageviews2881 data points1 Jan 2019 to 20 Nov 2026